Celldex Therapeutics buy Guggenheim
Start price
27.02.24
/
50%
€47.20
Target price
27.02.25
€82.92
Performance (%)
-59.11%
End price
28.02.25
€19.30
Summary
This prediction ended on 28.02.25 with a price of €19.30. The BUY prediction by Guggenheim for Celldex Therapeutics performed very badly with a performance of -59.11%. Guggenheim has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| Celldex Therapeutics | -9.735% | -9.735% | -15.702% |
| iShares Core DAX® | -1.553% | -0.123% | 12.654% |
| iShares Nasdaq 100 | -0.386% | -0.595% | 4.546% |
| iShares Nikkei 225® | 1.640% | 5.468% | 17.939% |
| iShares S&P 500 | 0.114% | -0.217% | 1.586% |
Comments by Guggenheim for this prediction
In the thread Celldex Therapeutics diskutieren
Celldex Therapeutics, Inc. (NASDAQ: CLDX) had its price target raised by analysts at Guggenheim from $72.00 to $90.00. They now have a "buy" rating on the stock.
Ratings data for CLDX provided by MarketBeat
In the thread Trading Celldex Therapeutics
Die von Guggenheim gewählte maximale Laufzeit wurde überschritten